Loading...
•
Mar 31
LabCorp Q1 2025 Earnings Report
Labcorp reported steady performance with revenue and adjusted EPS growth in Q1 2025.
Key Takeaways
Labcorp delivered solid first-quarter results with revenue growth and the successful launch of new diagnostic tests, despite a dynamic macroeconomic environment.
Revenue increased to $3.35 billion driven by organic growth and acquisitions.
Adjusted EPS rose to $3.84, reflecting operational efficiencies.
Net income was $212.8 million, slightly down year-over-year.
Launched new tests for cancer and Alzheimer's diagnosis, expanding the portfolio.
LabCorp
LabCorp
LabCorp Revenue by Segment
Revenue by Segment
Diagnostics Revenue
CapyFin.comBiopharma Lab Services Revenue
CapyFin.com Forward Guidance
Labcorp reaffirmed revenue and free cash flow guidance for 2025, while slightly raising the midpoint of adjusted EPS guidance.
Positive Outlook
- Revenue growth expected between 6.7% and 8.0% for 2025.
- Adjusted EPS guidance raised midpoint by $0.05 to $15.70-$16.40 range.
- Strong pipeline of acquisitions and partnerships in place.
- Expanded test menu in oncology, women's health, autoimmune disease, and neurology.
- Free cash flow projected between $1.10 billion and $1.25 billion.
Challenges Ahead
- Macroeconomic environment remains dynamic and challenging.
- Operating income margin decreased slightly year-over-year.
- Higher personnel costs impacting margins.
- Negative impacts from weather and fewer revenue days in Q1.
- Foreign exchange rates pose minor headwinds to revenue growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income